Last reviewed · How we verify
NCT06728280
Efficacy and Safety of DTMS in Adolescent Major Depressive Disorder
NA trial testing deep transcranial magnetic stimulation with H1coil in Major Depressive Diorder in 100 participants. Currently enrolling.
31 December 2025
Quick facts
| Lead sponsor | Zhifen Liu |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 100 |
| Start date | 31 December 2024 |
| Primary completion | 31 December 2025 |
| Estimated completion | 30 June 2026 |
| Sites | 2 locations across China |
Drugs / interventions tested
- deep transcranial magnetic stimulation with H1coil
- deep transcranial magnetic stimulation with H7 coil
Conditions studied
- Major Depressive Diorder — all drugs for Major Depressive Diorder →
Sponsor
Zhifen Liu
Who can join
Adults 11 to 23, any sex, with Major Depressive Diorder. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this randomized controlled trial is to explore the efficacy and safety of two different dTMS devices in adolescent depression: deep TMS H1 coil and deep TMS H7 coil. The main questions it aims to answer are: Type of study: Clinical trial. Participant population: Adolescents with major depressive disorder (MDD). Objective: To explore whether the H7 coil is no less effective than the H1 coil for adolescents with MDD, further providing clinicians with additional treatment options for patients.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06728280
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Major Depressive Diorder
Currently open trials in the same condition.
- NCT07281352 — RCT of Psilocybin-assisted CBT for Depression · Phase 1, PHASE2 · recruiting
- NCT07362511 — Imagery Rescripting in Primary Care · NA · recruiting
- NCT06641726 — Creating a Global Research Database That Connects Genetic Information and Long-term Health Data to Improve Personalized · recruiting
- NCT06719427 — qEEG Brain Signature of Depression & Neuromodulation-induced Recovery · Phase 1 · recruiting
- NCT06616116 — Stress Management with Real-time Bio-signal Biofeedback · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06728280 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhifen Liu
- Last refreshed: 12 March 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06728280.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing